Abstract
Objectives: Natalizumab is a humanized monoclonal antibody inhibiting lymphocyte migration and prescribed in patients with Crohn disease (CD) failing anti-tumor necrosis factor (TNF) therapies. Because of the risk of progressive multifocal leukoencephalopathy in patients with John Cunningham virus (JCV) positive, natalizumab is not widely used in clinical practice. Published experience of the use of natalizumab in pediatric patients is lacking. We aimed to describe the experience of natalizumab in patients with CD, including those who are JCV positive, at a tertiary care pediatric inflammatory bowel disease center. Methods: A retrospective chart review was performed in patients with CD 0.9 (median 3.36). There were no serious adverse events, including progressive multifocal leukoencephalopathy. All of the patients were transitioned to vedolizumab. Conclusions: In our experience, natalizumab is a safe and efficacious medication in pediatric in patients with inflammatory bowel disease. Given the favorable results with natalizumab, pediatric studies with the more gut targeted anti-integrin agent vedolizumab are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 863-866 |
| Number of pages | 4 |
| Journal | Journal of Pediatric Gastroenterology and Nutrition |
| Volume | 62 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2016 |
| Externally published | Yes |
Keywords
- anti-adhesion
- Crohn disease
- inflammatory bowel disease
- natalizumab
- pediatric IBD
- pediatrics
ASJC Scopus subject areas
- Gastroenterology
- Pediatrics, Perinatology, and Child Health